PE20191102A1 - Anticuerpos anti-pd-1 y sus usos - Google Patents
Anticuerpos anti-pd-1 y sus usosInfo
- Publication number
- PE20191102A1 PE20191102A1 PE2019000521A PE2019000521A PE20191102A1 PE 20191102 A1 PE20191102 A1 PE 20191102A1 PE 2019000521 A PE2019000521 A PE 2019000521A PE 2019000521 A PE2019000521 A PE 2019000521A PE 20191102 A1 PE20191102 A1 PE 20191102A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- human
- cdr1
- cdr2
- cdr3
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 abstract 1
- 102000048362 human PDCD1 Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Referido a un anticuerpo anti-PD humano que se une especificamente a PD-1 humano que tiene una secuencia de aminoacidos correspondiente a la SEQ ID NO: 1, en donde el anticuerpo comprende una cadena VH, que comprende tres CDR; y una cadena VL que comprende tres CDR, en donde: VH CDR1 es GYTFTHYGMN (SEQ ID NO:11); VH CDR2 es WVNTYTGEPTYADDFKG (SEQ ID NO:12); VH CDR3 es EGEGLGFGD (SEQ ID NO: 13); VL CDR1 es RSSQSIVHSHGDTYLE (SEQ ID NO:14); VL CDR2 es KVSNRFS (SEQ ID NO:15); y VL CDR3 es FQGSHIPVT (SEQ ID NO:16). En donde el anticuerpo anti-PD humano, comprende un dominio CH2 variante que tiene las sustituciones de aminoacido L234A y L235A. Tambien se refiere a metodos de preparacion y sus usos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394314P | 2016-09-14 | 2016-09-14 | |
| PCT/US2017/051531 WO2018053106A1 (en) | 2016-09-14 | 2017-09-14 | Anti-pd-1(cd279) antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191102A1 true PE20191102A1 (es) | 2019-08-23 |
Family
ID=59955732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000521A PE20191102A1 (es) | 2016-09-14 | 2017-09-14 | Anticuerpos anti-pd-1 y sus usos |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US9914783B1 (es) |
| EP (2) | EP3512547B1 (es) |
| JP (1) | JP7079773B2 (es) |
| KR (2) | KR102561356B1 (es) |
| CN (1) | CN109789205B (es) |
| AU (1) | AU2017326329B2 (es) |
| BR (1) | BR112019004998A2 (es) |
| CA (1) | CA3035932A1 (es) |
| CL (2) | CL2019000628A1 (es) |
| CO (1) | CO2019003154A2 (es) |
| CR (1) | CR20190199A (es) |
| CY (1) | CY1123642T1 (es) |
| DK (1) | DK3512547T3 (es) |
| DO (1) | DOP2019000056A (es) |
| EC (1) | ECSP19026178A (es) |
| ES (1) | ES2837755T3 (es) |
| HR (1) | HRP20201993T1 (es) |
| HU (1) | HUE051700T2 (es) |
| IL (2) | IL306104A (es) |
| LT (1) | LT3512547T (es) |
| MX (1) | MX2019002946A (es) |
| MY (1) | MY192158A (es) |
| PE (1) | PE20191102A1 (es) |
| PH (1) | PH12019500540A1 (es) |
| PL (1) | PL3512547T3 (es) |
| PT (1) | PT3512547T (es) |
| RS (1) | RS61204B1 (es) |
| RU (1) | RU2752562C2 (es) |
| SG (1) | SG10201914120XA (es) |
| SI (1) | SI3512547T1 (es) |
| SM (1) | SMT202000691T1 (es) |
| UA (1) | UA124631C2 (es) |
| WO (1) | WO2018053106A1 (es) |
| ZA (1) | ZA201902265B (es) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108368170B (zh) | 2015-07-13 | 2022-04-15 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| CA2991628C (en) | 2015-07-16 | 2020-04-07 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
| EA201891093A1 (ru) | 2015-11-03 | 2018-10-31 | Янссен Байотек, Инк. | Антитела, специфически связывающие pd-1, и их применение |
| IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| ES2837755T3 (es) * | 2016-09-14 | 2021-07-01 | Abbvie Biotherapeutics Inc | Anticuerpos anti-PD-1 |
| PL3532607T3 (pl) | 2016-10-26 | 2024-07-01 | Iovance Biotherapeutics, Inc. | Restymulacja kriokonserwowanych limfocytów naciekających guza nowotworowego |
| KR102536145B1 (ko) | 2017-01-20 | 2023-05-30 | 타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 | 항-pd-1 항체 및 이의 용도 |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11819517B2 (en) | 2017-06-05 | 2023-11-21 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| CR20190550A (es) | 2017-06-05 | 2020-04-05 | Janssen Biotech Inc | Anticuerpos que se unen específicamente a pd-1 y métodos de uso |
| WO2019032241A1 (en) | 2017-07-13 | 2019-02-14 | Northwestern University | GENERAL AND DIRECT METHOD FOR PREPARING NANOPARTICLES WITH ORGANOMETALLIC STRUCTURE FUNCTIONALIZED BY OLIGONUCLEOTIDES |
| KR20200045520A (ko) | 2017-09-07 | 2020-05-04 | 오거스타 유니버시티 리서치 인스티튜트, 인크. | 프로그래밍된 세포사 단백질 1에 대한 항체 |
| WO2019083971A1 (en) | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| BR112020013848A2 (pt) | 2018-01-08 | 2020-12-01 | Iovance Biotherapeutics, Inc. | métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| WO2019160751A2 (en) | 2018-02-13 | 2019-08-22 | Merck Sharp & Dohme Corp. | Methods for treating cancer with anti-pd-1 antibodies |
| EP3784254A1 (en) | 2018-04-27 | 2021-03-03 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| AU2019306504A1 (en) | 2018-07-15 | 2021-03-11 | Renovaro Biosciences Inc. | Methods and compositions using recombinant dendritic cells for cancer therapy |
| CN112424231B (zh) | 2018-07-19 | 2022-09-13 | 大有华夏生物医药集团有限公司 | 抗pd-1抗体及其剂量和用途 |
| EP3877513B1 (en) | 2018-11-05 | 2025-05-07 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| WO2020127367A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Humanized anti-human-pd-1 antibody |
| US20230071889A1 (en) | 2018-12-21 | 2023-03-09 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| AU2019409805A1 (en) | 2018-12-21 | 2021-07-22 | Ose Immunotherapeutics | Bifunctional anti-PD-1/SIRPA molecule |
| KR20210106531A (ko) * | 2018-12-21 | 2021-08-30 | 에임 이뮤노테크 인코포레이티드 | 암 치료를 위한 조성물 및 방법 |
| WO2020127369A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional molecule directed against human pd-1 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| CA3129585A1 (en) * | 2019-02-18 | 2020-08-27 | Medivir Aktiebolag | Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
| WO2020176846A2 (en) * | 2019-02-28 | 2020-09-03 | The Rockefeller University | Apoe genotyping in cancer prognostics and treatment |
| EP3976090A1 (en) | 2019-05-24 | 2022-04-06 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| US20220372148A1 (en) | 2019-07-05 | 2022-11-24 | Ono Pharmaceutical Co., Ltd. | A pharmaceutical composition for treating hematological cancer |
| US20220332825A1 (en) | 2019-08-08 | 2022-10-20 | Ono Pharmaceutical Co., Ltd. | Bispecific protein |
| US12319711B2 (en) | 2019-09-20 | 2025-06-03 | Northwestern University | Spherical nucleic acids with tailored and active protein coronae |
| US12378560B2 (en) | 2019-10-29 | 2025-08-05 | Northwestern University | Sequence multiplicity within spherical nucleic acids |
| RS65646B1 (sr) | 2019-12-13 | 2024-07-31 | Inspirna Inc | Soli metala i njihove upotrebe |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| JP2023514056A (ja) * | 2020-02-07 | 2023-04-05 | バイオエクセル セラピューティクス，インコーポレイテッド | 免疫調節を使用した癌の治療レジメン |
| IL298431A (en) * | 2020-05-26 | 2023-01-01 | Boehringer Ingelheim Int | Anti-pd-1 antibodies |
| EP4204454A4 (en) * | 2020-08-31 | 2024-07-24 | Biosion, Inc. | PD-1 BINDING ANTIBODIES AND THEIR USES |
| CA3197951A1 (en) * | 2020-11-11 | 2022-05-19 | Ugur Sahin | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
| WO2022118197A1 (en) | 2020-12-02 | 2022-06-09 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
| KR20230129441A (ko) | 2020-12-17 | 2023-09-08 | 오제 이뮈노테라프틱스 | 이기능성 항-pd1/il-7 분자 |
| WO2022214653A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| KR20240137086A (ko) * | 2022-01-28 | 2024-09-19 | 조지아뮨 인코포레이티드 | Pd-1 작용제인 세포예정사 단백질 1에 대한 항체 |
| CN119013304A (zh) * | 2022-03-04 | 2024-11-22 | 翠舒拉治疗股份有限公司 | 在胃癌中使用抗人cd39抗体、抗人pd-1抗体和化疗的组合 |
| EP4507704A1 (en) | 2022-04-15 | 2025-02-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
| CN119907811A (zh) | 2022-08-02 | 2025-04-29 | Ose免疫疗法公司 | 针对cd28的多功能分子 |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| US20250059280A1 (en) | 2023-08-15 | 2025-02-20 | Abbvie Inc. | Methods of treating human immunodeficiency virus (hiv) disease |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| JPH07291996A (ja) | 1994-03-01 | 1995-11-07 | Yuu Honshiyo | ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物 |
| KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| KR100663319B1 (ko) | 1997-04-14 | 2007-01-02 | 마이크로메트 에이지 | 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| EP1135498B1 (en) | 1998-11-18 | 2008-01-23 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| AU7072700A (en) | 1999-08-23 | 2001-03-19 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| NZ517122A (en) | 1999-08-23 | 2004-02-27 | Dana Farber Cancer Inst Inc | Novel B7-4 molecules and uses therefor |
| JP2004533226A (ja) | 2001-04-02 | 2004-11-04 | ワイス | Ｂ７−４に対するｐｄ−１、ａレセプター、およびその使用 |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| WO2003006636A1 (de) | 2001-07-12 | 2003-01-23 | Genethor Gmbh | Reduktion der stimulationsfähigkeit von antigen präsentierenden zellen |
| ATE524495T1 (de) | 2001-07-31 | 2011-09-15 | Ono Pharmaceutical Co | Pd-1-spezifische substanz |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
| WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトｐｄ−１に対し特異性を有する物質 |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| KR20080000613A (ko) | 2005-03-25 | 2008-01-02 | 제넨테크, 인크. | 과안정화된 ｃ-ｍｅｔ의 조절을 위한 방법 및 조성물 |
| NZ563193A (en) * | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| US20100040614A1 (en) * | 2006-12-27 | 2010-02-18 | Rafi Ahmed | Compositions and methods for the treatment of infections and tumors |
| US20080292625A1 (en) * | 2007-04-18 | 2008-11-27 | Sally Schroeter | Prevention and treatment of cerebral amyloid angiopathy |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP2350129B1 (en) * | 2008-08-25 | 2015-06-10 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| WO2014093786A1 (en) * | 2012-12-14 | 2014-06-19 | Abbvie, Inc. | Methods for increasing the efficiency of hybridoma generation |
| TW201920283A (zh) | 2012-12-24 | 2019-06-01 | 美商艾伯維有限公司 | 催乳激素受體結合蛋白質及其用途 |
| JP6449229B2 (ja) | 2013-03-15 | 2019-01-09 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Ｆｃ変異体 |
| CN104250302B (zh) * | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| CN106459200B (zh) | 2014-03-21 | 2019-12-06 | 艾伯维公司 | 抗-egfr抗体及抗体药物偶联物 |
| CA2949327A1 (en) | 2014-05-29 | 2015-12-03 | Medimmune Limited | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers |
| CA2966005C (en) | 2014-10-31 | 2021-04-27 | Abbvie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| EP3215538A4 (en) * | 2014-11-07 | 2018-07-04 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
| CA3175979A1 (en) * | 2014-12-22 | 2016-06-30 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
| JP2019500327A (ja) | 2015-11-30 | 2019-01-10 | アッヴィ・インコーポレイテッド | 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法 |
| CA3006610A1 (en) * | 2015-11-30 | 2017-06-08 | Abbvie Inc. | Anti-hulrrc15 antibody drug conjugates and methods for their use |
| BR112018069297A2 (pt) * | 2016-03-21 | 2019-01-22 | Patel Ami | composição, e, métodos para induzir uma resposta imune e para tratar um indivíduo que foi diagnosticado com uma doença ou distúrbio |
| ES2837755T3 (es) * | 2016-09-14 | 2021-07-01 | Abbvie Biotherapeutics Inc | Anticuerpos anti-PD-1 |
-
2017
- 2017-09-14 ES ES17772258T patent/ES2837755T3/es active Active
- 2017-09-14 SG SG10201914120XA patent/SG10201914120XA/en unknown
- 2017-09-14 PE PE2019000521A patent/PE20191102A1/es unknown
- 2017-09-14 MY MYPI2019001212A patent/MY192158A/en unknown
- 2017-09-14 LT LTEP17772258.4T patent/LT3512547T/lt unknown
- 2017-09-14 HU HUE17772258A patent/HUE051700T2/hu unknown
- 2017-09-14 IL IL306104A patent/IL306104A/en unknown
- 2017-09-14 BR BR112019004998A patent/BR112019004998A2/pt unknown
- 2017-09-14 RS RS20201518A patent/RS61204B1/sr unknown
- 2017-09-14 HR HRP20201993TT patent/HRP20201993T1/hr unknown
- 2017-09-14 PT PT177722584T patent/PT3512547T/pt unknown
- 2017-09-14 SI SI201730531T patent/SI3512547T1/sl unknown
- 2017-09-14 CA CA3035932A patent/CA3035932A1/en active Pending
- 2017-09-14 JP JP2019512990A patent/JP7079773B2/ja active Active
- 2017-09-14 SM SM20200691T patent/SMT202000691T1/it unknown
- 2017-09-14 MX MX2019002946A patent/MX2019002946A/es unknown
- 2017-09-14 PL PL17772258T patent/PL3512547T3/pl unknown
- 2017-09-14 UA UAA201903714A patent/UA124631C2/uk unknown
- 2017-09-14 EP EP17772258.4A patent/EP3512547B1/en active Active
- 2017-09-14 AU AU2017326329A patent/AU2017326329B2/en active Active
- 2017-09-14 RU RU2019110835A patent/RU2752562C2/ru active
- 2017-09-14 EP EP20196903.7A patent/EP3778643A1/en not_active Withdrawn
- 2017-09-14 IL IL265179A patent/IL265179B2/en unknown
- 2017-09-14 KR KR1020197010300A patent/KR102561356B1/ko active Active
- 2017-09-14 WO PCT/US2017/051531 patent/WO2018053106A1/en not_active Ceased
- 2017-09-14 DK DK17772258.4T patent/DK3512547T3/da active
- 2017-09-14 CN CN201780055621.1A patent/CN109789205B/zh active Active
- 2017-09-14 CR CR20190199A patent/CR20190199A/es unknown
- 2017-09-14 KR KR1020237025514A patent/KR20230114331A/ko not_active Withdrawn
- 2017-09-14 US US15/704,296 patent/US9914783B1/en active Active
-
2018
- 2018-01-19 US US15/875,970 patent/US20180148513A1/en not_active Abandoned
-
2019
- 2019-03-11 DO DO2019000056A patent/DOP2019000056A/es unknown
- 2019-03-12 CL CL2019000628A patent/CL2019000628A1/es unknown
- 2019-03-13 PH PH12019500540A patent/PH12019500540A1/en unknown
- 2019-03-29 CO CONC2019/0003154A patent/CO2019003154A2/es unknown
- 2019-04-10 ZA ZA2019/02265A patent/ZA201902265B/en unknown
- 2019-04-12 EC ECSENADI201926178A patent/ECSP19026178A/es unknown
- 2019-10-22 US US16/660,634 patent/US10730953B2/en active Active
- 2019-12-11 CL CL2019003627A patent/CL2019003627A1/es unknown
-
2020
- 2020-06-22 US US16/907,794 patent/US20200317808A1/en not_active Abandoned
- 2020-12-09 CY CY20201101165T patent/CY1123642T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191102A1 (es) | Anticuerpos anti-pd-1 y sus usos | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| PE20120497A1 (es) | Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| CL2018003583A1 (es) | Anticuerpos anti-pd-l1 y usos de los mismos. | |
| PE20190356A1 (es) | Receptores quimericos y metodos de uso de los mismos | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20130159A1 (es) | Anticuerpos anti-cd40 | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| MY200988A (en) | CD3 Binding Antibodies | |
| PE20191031A1 (es) | ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS | |
| CL2020002223A1 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| CY1121158T1 (el) | Αντισωμα ικανο να αναγνωριζει ειδικα υποδοχεα τρανσφερρινης | |
| NZ718973A (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20211887A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
| PE20121649A1 (es) | Anticuerpos monoclonales frente a progastrina y sus usos | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| AR099855A1 (es) | Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso | |
| PE20211291A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| PE20190261A1 (es) | Anticuerpos que reconocen tau |